Grace Therapeutics, Inc.

GRCE Nasdaq SEC CIK 1444192
Follow Grace Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2027 USD · US GAAP
Net income −$2.1M −127.2% vs same quarter last year
EPS, diluted −$0.11 −83.3% vs same quarter last year
Operating cash flow −$1.8M +43.2% vs same quarter last year
Operating income −$2.3M +9.4% vs same quarter last year
Net income by quarter
−$4.2M
$636K
−$3.4M
−$938K
−$2.3M
−$1.2M
−$15.8M
−$2.1M
Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$60M−$40M−$20M$0FY18FY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearNet income
FY26−$7.8M
FY25−$9.6M
FY24−$12.9M
FY23−$42.4M
FY22−$9.8M
FY21−$19.7M
FY20−$25.5M
FY19−$39.4M
FY18-